title: [Control of innate immune system for cancer therapy].
abstract: Immunotherapies are particularly attractive when one wants to fight cancer since they aim at controlling the immune system in order to eradicate cancer cells and prevent tumor dissemination. While the clinical use of specific ligands for the innate immune receptors is promising, it is still facing several drawbacks when entering clinical trials. Nevertheless, recent advances in our understanding of the biology of these receptors constrain us to re-assess existing strategies and let foresee new approaches in the pipeline of therapies that would overcome current limitations.
authors.affiliation: Département de biologie vasculaire et d'inflammation, Centre national d'investigations cardiovasculaires, Calle Melchor Fernández de Almagro, 3, 28029 Madrid, Espagne  - Inserm, U1040, institut de recherche en biothérapie, 80, avenue Augustin Fliche, 34293 Montpellier Cedex 5, France.
authors.forename: Johan
authors.initials: J
authors.lastname: Garaude
mesh_terms: D019496:Cancer Vaccines; D006801:Humans; D007167:Immunotherapy; D058847:Inflammasomes; D007249:Inflammation; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D011971:Receptors, Immunologic; D051193:Toll-Like Receptors
chemical_list: D019496:Cancer Vaccines; D058847:Inflammasomes; D011971:Receptors, Immunologic; D051193:Toll-Like Receptors